Table A4.
Factors associated with intracranial progression-free survival.
| Variables | Univariate | Multivariable Model 5 | Multivariable Model 6 |
|---|---|---|---|
| OP (vs. no OP) | 0.97 [0.53–1.79] | ||
| RT (vs. no RT) | 0.76 [0.42–1.36] | ||
| OP or RT (vs. no OP or RT) | 1.05 [0.60–1.83] | 0.95 [0.51–1.77] | 1.02 [0.52–2.02] |
| EGFR TKI: (vs. gefitinib) | |||
| Erlotinib | 1.41 [0.54–3.70] | 1.36 [0.47–3.95] | 1.34 [0.44–4.11] |
| Afatinib | 1.59 [0.60–4.23] | 1.59 [0.57–4.45] | 1.58 [0.55–4.52] |
| Osimertinib | † | † | † |
| Anti-VEGF treatment (vs. no anti-VEGF) |
2.04 [0.63–6.65] | 1.81 [0.52–6.29] | 1.44 [0.39–5.39] |
| Male (vs. female) | 1.70 [0.94–3.07] | 1.51 [0.82–2.80] | 1.38 [0.74–2.58] |
| Age (≥65 vs. <65) | 0.71 [0.40–1.28] | 0.69 [0.37–1.29] | 0.65 [0.33–1.27] |
| ECOG PS (≥2 vs. ≤1) | 0.77 [0.31–1.96] | 0.94 [0.33–2.63] | 1.17 [0.40–3.41] |
| Exon 19 deletion vs. L858R | 0.76 [0.44–1.34] | 0.72 [0.39–1.32] | 0.73 [0.39–1.36] |
| PD-L1 ≥ 1% vs. PD-L1 < 1% or not tested |
1.43 [0.81–2.54] | 1.39 [0.75–2.56] | 1.50 [0.79–2.84] |
| Number of brain metastases (≥5 vs. <5) | 0.69 [0.38–1.27] | 0.66 [0.35–1.26] | 0.58 [0.29–1.14] |
| Extracranial metastasis (vs. no) | 1.12 [0.52–2.39] | 1.18 [0.53–2.63] | |
| Lung metastasis (vs. no) | 1.20 [0.69–2.09] | 1.37 [0.70–2.67] | |
| Pleural metastasis/effusion (vs. no) | 0.87 [0.49–1.55] | 0.95 [0.47–1.95] | |
| Bone metastasis (vs. no) | 1.43 [0.79–2.60] | 1.32 [0.66–2.64] | |
| Liver metastasis (vs. no) | 1.16 [0.55–2.48] | 1.10 [0.46–2.63] | |
| Pericardial metastasis/effusion (vs. no) | 0.86 [0.45–1.65] | 0.72 [0.32–1.60] | |
| Adrenal metastasis (vs. no) | 1.59 [0.62–4.07] | 2.30 [0.79–6.70] | |
| Other metastasis (vs. no) | 0.56 [0.08–4.10] | 0.52 [0.06–4.47] |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; OP, surgery for brain tumor; PD-L1, programmed death ligand 1; PS, performance status; RT, radiotherapy for brain tumor; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor. A patient with cancer harboring both the exon 19 deletion and L858R was included in the exon 19 deletion group. Data are presented as hazard ratio (HR) with a 95% confidence interval. † HR could not be assessed due to no event in a group.